Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo

Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Wright, Laura E., Harhash, Ahmed A., Kozlow, Wende M., Waning, David L., Regan, Jenna N., She, Yun, John, Sutha K., Murthy, Sreemala, Niewolna, Maryla, Marks, Andrew R., Mohammad, Khalid S., Guise, Theresa A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2016
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352410/
https://ncbi.nlm.nih.gov/pubmed/28039445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14139
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller